Piramal Pharma Limited — Investor Meet, 29-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Piramal Pharma delivered robust Q1 FY27 results: revenue grew 17% YoY to ₹2,270 Cr, and EBITDA surged 72% to ₹285 Cr, expanding margins to 12.5%. All segments saw strong performance: CDMO +19%, Complex Hospital Generics +17%, and Consumer Healthcare +15%. Management highlighted strong execution, healthy CDMO order inflows, market leadership in key CHG therapies, and robust growth in PCH's Power Brands and e-commerce. The company is confident about sustained revenue and EBITDA expansion. Piramal Pharma has announced an earnings conference call on July 30, 2026, to discuss its Q1 FY27 results.